Fig. 3From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraineMaintenance of response. Percentage of patients treated with monthly injections of galcanezumab 120Â mg or 240Â mg, who had at least 50% or greater reduction from baseline in migraine headache days and maintained at least 40% reduction over 3 to 12 consecutive monthsBack to article page